Duchenne Muscular Dystrophy Treatment Market to Reach USD 9.78 Billion by 2030; Driven by Gene and Exon-Skipping Therapies

Mordor Intelligence has published a new report on the Duchenne Muscular Dystrophy Treatment Market, offering a comprehensive analysis of trends, growth drivers, and future projections.

The global Duchenne Muscular Dystrophy (DMD) treatment market is projected to be worth USD 4.07 billion in 2025, expanding to USD 9.78 billion by 2030, at a compound annual growth rate (CAGR) of 19.13 percent. This marked growth is fuelled by cutting-edge therapies including gene therapy, exon-skipping drugs, and recently approved anti-inflammatory agents. North America currently dominates in revenue share, while the Asia-Pacific region is emerging at the fastest pace. As new treatments secure regulatory approval, the DMD treatment landscape is entering a dynamic phase that promises improved outcomes for patients and significant market opportunities.

Report Overview: https://www.mordorintelligence.com/industry-reports/duchenne-muscular-dystrophy-treatment-market?utm_source=openpr

Key Trends

1. Gene therapy gains momentum
The FDA's first-ever approval of Elevidys (delandistrogene moxeparvovec) in June 2023 signalled the arrival of gene therapy for young DMD patients. Initially indicated for ambulatory children aged 4-5, the therapy has since expanded for broader age and mobility groups, greatly enlarging patient access. Its high cost approximately USD 3.2 million per infusion places it among the most expensive treatments but reflects its groundbreaking potential.

2. Exon-skipping therapies advance
Several exon-skipping agents are already available in the US, offering tailored treatment for specific genetic profiles:

Casimersen (Amondys 45) targets exon 45 mutations; FDA-approved in February 2021.

Viltolarsen (Viltepso), for exon 53 mutations, gained approval in August 2020
These therapies have broadened options for roughly 8% of DMD patients.

3. Non-steroidal treatments approved
In March 2024, the FDA approved givinostat (Duvyzat) for ambulatory patients aged 6 and older-the first non-steroidal option covering all genetic variants of DMD That was followed in late 2023 by approval of vamorolone (Agamree), a steroid analogue with fewer side effects .Both approvals offer additional, more tolerable alternatives to traditional corticosteroids.

4. Regional growth shifts
North America continues to hold the largest share of the DMD treatment market However, Asia‐Pacific is growing fastest, with improved diagnosis rates, regulatory support, and healthcare investment contributing to faster uptake.

Market Segmentation

The DMD treatment market can be broken down as follows:

By Therapeutic Approach

Molecular-based Therapies

Steroid Therapy (corticosteroids)

Other Therapeutic Approaches

By Geography

North America

Europe

Asia‐Pacific

Rest of the world

Explore Our Full Library of Healthcare Research Industry Reports:

https://www.mordorintelligence.com/market-analysis/healthcare?utm_source=openpr

Key Players

Nippon Shinyaku Co., Ltd. (NS Pharma Inc.)
A Japanese pharmaceutical company focused on innovative therapies. NS Pharma holds a significant presence in DMD through its development and commercialization efforts.

Italfarmaco S.p.A.
A healthcare and pharmaceutical company based in Italy. Italfarmaco is notably developing givinostat, an oral non-steroidal agent for DMD, which has received FDA approval in March 2024 and an EU recommendation in April 2025.

PTC Therapeutics
A U.S.-based biopharmaceutical firm specializing in rare genetic disorders. They concentrate on exon-skipping therapies and have brought deflazacort (Emflaza) and exon-specific drugs to market.

Santhera Pharmaceuticals
A Swiss company that, in partnership with Catalyst Pharmaceuticals, brought vamorolone (Agamree) to market in October 2023. This corticosteroid alternative aims for improved tolerability.

Sarepta Therapeutics
A leader in DMD treatment, spearheading development of exon-skipping drugs (like golodirsen, viltolarsen, and casimersen) and delivering the first FDA-approved gene therapy, Elevidys (delandistrogene moxeparvovec), in June 2023.

Conclusion

The Duchenne Muscular Dystrophy treatment market is set for significant expansion over the next five years, driven by advanced gene therapies, targeted exon-skipping drugs, and safer oral agents. From an estimated USD 4.07 billion in 2025, it is expected to surpass USD 9.78 billion by 2030.

North America remains the leader in treatment adoption and investment, while Asia‐Pacific emerges as a high-growth region with increasing diagnosis rates and improving access. Key companies like Sarepta, Santhera, Italfarmaco, and PTC Therapeutics are at the forefront, translating research breakthroughs into new treatment options for patients.

Notable developments-such as Elevidys' expansion beyond initial age restrictions, approvals for non-steroidal treatments, and evolving clinical use of exon-skipping medications-indicate a broadening and more mature DMD market. As these therapies continue to be refined, and as healthcare systems adapt to support their rollout, patients and caregivers can expect more treatment choices, offering hope for better quality of life and long-term outcomes.

Industry Related Reports

Global Antisense and RNAi Therapeutics Market: The Antisense & RNAi Therapeutics Market report segments the industry into By Therapeutics (RNA Interference, RNA Antisense), By Route of Administration (Intravenous Route, Subcutaneous Route, Intrathecal Route, Pulmonary Delivery, Intraperitoneal Injection, Others), By Indication (Autosomal Recessive Disease, Autosomal Dominant Disease, Chromosomal Disease, Others), and Geography (North America, Europe, Asia-Pacific, and more.)

Get More Insights: https://www.mordorintelligence.com/industry-reports/antisense-and-rnai-therapeutics-market?utm_source=openpr

Rare Neurological Disease Treatment Market: The report covers Rare Neurological Disorders Market Trends, and the market is segmented by Segmented by Drug Type (Biologics and Small Molecules), Mode of Administration (Intravenous and Oral), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market provides the value (in USD million) for the above-mentioned segments.

Get More Insights: https://www.mordorintelligence.com/industry-reports/rare-neurological-disease-treatment-market?utm_source=openpr

Gene Therapy Market : The Gene Therapy Market Report Segments the Industry Into by Vector Type (Adeno Virus Vector, and More), Indication (Oncology, Rare Metabolic Disorders, and More), Delivery Mode (In Vivo Gene Delivery and Ex Vivo Gene Delivery), End User (Hospitals and Clinics, and More), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD)

Get More Insights: https://www.mordorintelligence.com/industry-reports/gene-therapy-market?utm_source=openpr

About Mordor Intelligence:

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

For any inquiries or to access the full report, please contact:

media@mordorintelligence.com
https://www.mordorintelligence.com/

Mordor Intelligence, 11th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli, Hyderabad, Telangana - 500032, India

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

For any inquiries or to access the full report, please contact:

media@mordorintelligence.com
https://www.mordorintelligence.com/

This release was published on openPR.